Targeting EGFR in bilio-pancreatic and liver carcinoma

Maria Elisabetta Fratto, Daniele Santini, Bruno Vincenzi, Nicola Silvestris, Amalia Azzariti, Stefania Tommasi, Alice Zoccoli, Sara Galluzzo, Evaristo Maiello, Giuseppe Colucci, Giuseppe Tonini

Research output: Contribution to journalArticlepeer-review


The key role of epidermal growth factor receptor (EGFR) in tumorigenesis has been demonstrated in several cancer types, so recent clinical trials have investigated their activity/efficacy in different settings. Two different types of EGFR-targeted agents were developed: monoclonal antibodies such as cetuximab and panitumumab, and tyrosine kinase inhibitors, such as gefitinib and erlotinib. In this review, we summarize the preclinical rational of potential activity and the most important clinical trials evaluated anti-EGFR targeted agents in non-colorectal digestive cancer, both in monotherapy and in combination with other chemotherapeutic or targeted agents. Patient selection by use of biologic markers will identify which patients are more likely to respond, contributing to the successful use of these agents.

Original languageEnglish
Pages (from-to)16-22
Number of pages7
JournalFrontiers in Bioscience - Scholar
Volume3 S
Issue number1
Publication statusPublished - Jan 1 2011


  • Anti-EGFR therapy
  • Biliary Tract Cancer
  • Gastric Cancer
  • Hepatocellular Cancer
  • Pancreatic Cancer
  • Review

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)


Dive into the research topics of 'Targeting EGFR in bilio-pancreatic and liver carcinoma'. Together they form a unique fingerprint.

Cite this